3,5-difluorophenyl-α-fluoroacetic acid | 208259-38-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,5-difluorophenyl-α-fluoroacetic acid
• 英文别名: α-Fluoro-3,5-difluorophenylacetic Acid；(3,5-difluorophenyl)fluoroacetic acid；2-(3,5-Difluorophenyl)-2-fluoroacetic acid
• CAS: 208259-38-5
• 化学式: C₈H₅F₃O₂
• 分子量: 190.122
• InChiKey: MZVNGSGHYLFNHX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3,5-difluorophenyl-α-fluoroacetic acid 、 3-(L-Alaninyl)-amino-2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepin-2-one 在 hexanes ethyl acetate 作用下， 生成 3-[N'-(3,5-difluorophenyl-α-fluoroacetyl)-L-alaninyl]amino-2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepin-2-one
  参考文献：
  名称：

  Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds

  摘要：

  本发明涉及抑制β-淀粉样肽释放和/或合成的化合物，因此在治疗阿尔茨海默病方面具有用途。本发明还公开了包括抑制β-淀粉样肽释放和/或合成的化合物的制药组合物，以及使用这种制药组合物预防和治疗阿尔茨海默病的方法。

  公开号：

  US20050203080A1
• 作为产物：
  描述：

  methyl α-fluoro-3,5-difluorophenylacetate 在 sodium hydroxide 、 盐酸 作用下， 以 甲醇 、 水 、 乙酸乙酯 为溶剂， 反应 18.0h， 生成 3,5-difluorophenyl-α-fluoroacetic acid
  参考文献：
  名称：

  Acylaminothiazole derivatives, their preparation and therapeutic use

  摘要：

  这项发明涉及一种通式(I)的化合物，其中：X代表氧或硫原子；R1代表，当n=2或3时独立地表示卤素原子、羟基、C1-C3烷基、C1-C3烷氧基、三氟甲基、三氟甲氧基或亚甲二氧基；R2代表可选地取代的C1-C6烷基基团、C3-C7环烷基、哌啶基或苯基，其中C3-C7环烷基、哌啶基或苯基可选地取代；R3代表氢原子或可选地取代的C1-C6烷基基团；R4代表氢原子或C1-C4烷基基团；R5和R5′独立地表示氢原子、羟基、卤素原子、C1-C3烷基基团，或者R5和R5′一起形成醛基；R6代表氢原子、卤素原子、C1-C3烷基、C1-C3烷氧基、三氟甲基或三氟甲氧基；以碱、酸盐、水合物或溶剂化合物的形式存在。该发明适用于治疗。

  公开号：

  US20040171643A1

文献信息

• Semirational Design of Fluoroacetate Dehalogenase RPA1163 for Kinetic Resolution of α-Fluorocarboxylic Acids on a Gram Scale
  作者：Hongxia Zhang、Shaixiao Tian、Yue Yue、Min Li、Wei Tong、Guangyu Xu、Bo Chen、Ming Ma、Yanwei Li、Jian-bo Wang

  DOI：10.1021/acscatal.9b04804

  日期：2020.3.6

  performance in the reactions of these substrates, while in silico calculations shed light on the origin of these improvements. Finally, 10 α-fluorocarboxylic acids and 10 α-hydroxycarboxylic acids were prepared on a gram scale via kinetic resolution enabled by WT, W185T, or W185N. This work expands the biocatalytic toolbox and allows a deep insight into the fluoroacetate dehalogenase catalyzed C–F cleavage

  在此，通过外消旋α-氟代羧酸的动力学拆分，探索了氟乙酸盐脱卤酶RPA1163的合成用途，用于生产对映体纯的（R）-α-氟代羧酸和（R）-α-羟基代羧酸。尽管野生型（WT）RPA1163显示出高的热稳定性和相当宽的底物范围，但仍然存在许多有趣但接受程度不高或中等的底物。为了解决该问题并发展规模化生产，采用了计算机模拟和半理性诱变。残基W185被设计用于丙氨酸，丝氨酸，苏氨酸或天冬酰胺。两种最佳的突变体W185N和W185T在这些底物的反应中表现出显着改善的性能，而在计算机上计算结果揭示了这些改进的起源。最后，通过WT，W185T或W185N实现的动力学拆分，以克为单位制备了10种α-氟代羧酸和10种α-羟基羧酸。这项工作扩展了生物催化工具箱，并允许深入了解氟乙酸盐脱卤酶催化的CF裂解机理。
• ORGANIC ELECTRONIC COMPONENT HAVING A CHARGE CARRIER GENERATION LAYER AND THE USE OF A ZINC COMPLEX AS A P-TYPE DOPANT IN CHARGE CARRIER GENERATION LAYERS
  申请人：OSRAM OLED GmbH

  公开号：US20180277778A1

  公开（公告）日：2018-09-27

  The invention relates to an organic electronic component ( 100 ) comprising at least one charge generation layer ( 5 ) which has an organically p-doped region ( 5 a ) that contains a zinc complex as a p-dopant, said zinc complex in turn containing at least one ligand L of the following structure: formula (I) wherein R1 and R2 can be oxygen, sulphur, selenium, NH or NR4 independently from one another, wherein R4 is selected from the group containing alkyl or aryl and which can be bonded to R3; and wherein R3 is selected from the group containing alkyl, long-chain alkyl, cycloalkyl, halogen alkyl, at least partially halogenated long-chain alkyl, halogen cycloalkyl, aryl, arylene, halogen aryl, heteroaryl, heteroarylene, heterocyclic alkylene, heterocycloalkyl, halogen heteroaryl, alkenyl, halogen alkenyl, alkynyl, halogen alkynyl, ketoaryl, halogen ketoaryl, ketoheteroaryl, ketoalkyl, halogen ketoalkyl, ketoalkenyl, halogen ketoalkenyl, halogen alkyl aryl, and halogen alkyl heteroaryl, wherein, for suitable groups, one or a number of non-adjacent CH2 groups can be replaced by —O—, —S—, —NH—, —NR ∘∘∘ —, —SiR ∘ R ∘∘ —, —CO—, —COO—, —COR ∘ OR ∘∘ —, —OCO—, —OCO—O—, —SO2-, —S—CO—, —CO—S—, —O—CS—, —CS—O—, —CY1=CY2 or —C≡C— independently from one another, and in such a way that O and/or S atoms are not directly bonded to one another, and are replaced optionally with aryl- or heteroaryl preferably containing between 1 and 30 C atoms (terminal CH3 groups are understood to be CH2 groups in the sense of CH2-H). The invention further relates to the use of a zinc complex as a p-dopant in charge generation layers.

  本发明涉及一种有机电子元件（100），包括至少一个具有有机p-掺杂区域（5a）的电荷生成层（5），该区域含有锌络合物作为p-掺杂剂，所述锌络合物又包含至少一个具有以下结构的配体L：式（I），其中R1和R2可以分别独立地为氧、硫、硒、NH或NR4，其中R4选自含有烷基或芳基的基团，可以与R3结合；R3选自含有烷基、长链烷基、环烷基、卤代烷基、至少部分卤代长链烷基、卤代环烷基、芳基、芳烯基、卤代芳基、杂环芳基、杂环芳烯基、杂环烷基、卤代杂环芳基、烯基、卤代烯基、炔基、卤代炔基、酮基芳基、卤代酮基芳基、酮基杂环芳基、酮基烷基、卤代酮基烷基、酮基烯基、卤代酮基烯基、卤代烷基芳基和卤代烷基杂环芳基的基团，对于适当的基团，一个或多个非相邻的CH2基团可以被—O—、—S—、—NH—、—NR∘∘∘—、—SiR∘R∘∘—、—CO—、—COO—、—COR∘OR∘∘—、—OCO—、—OCO—O—、—SO2-、—S—CO—、—CO—S—、—O—CS—、—CS—O—、—CY1=CY2或—C≡C—中的一个或多个代替，且使O和/或S原子不直接结合，可选地用含有1至30个C原子的芳基或杂环芳基替换（末端CH3基团在 -H的意义上被理解为 基团）。该发明还涉及在电荷生成层中使用锌络合物作为p-掺杂剂。
• Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting B-amyloid peptide release and/or its synthesis by use of such compounds
  申请人：——

  公开号：US20020173504A1

  公开（公告）日：2002-11-21

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  本发明涉及抑制&bgr;-淀粉样肽的释放和/或合成的化合物，因此具有治疗阿尔茨海默病的效用。还公开了包含抑制&bgr;-淀粉样肽释放和/或合成的化合物的药物组合物，以及使用这种药物组合物预防和治疗阿尔茨海默病的方法。
• Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis
  申请人：——

  公开号：US20030229024A1

  公开（公告）日：2003-12-11

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  本发明涉及一种抑制&bgr;-淀粉样肽释放和/或合成的化合物，因此具有治疗阿尔茨海默病的用途。还公开了药物组合物，包括抑制&bgr;-淀粉样肽释放和/或合成的化合物，以及使用这样的药物组合物进行预防和治疗阿尔茨海默病的方法。
• Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-Amyloid peptide release and/or its synthesis by use of such compounds
  申请人：——

  公开号：US20020111343A1

  公开（公告）日：2002-08-15

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  本发明涉及一种抑制β-淀粉样肽释放和/或合成的化合物，因此具有治疗阿尔茨海默病的效用。本发明还涉及包含抑制β-淀粉样肽释放和/或合成的化合物的制药组合物，以及使用这种制药组合物预防和治疗阿尔茨海默病的方法。